Literature DB >> 20445347

Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.

Karianne Risberg1, Oystein Fodstad, Yvonne Andersson.   

Abstract

We have earlier shown that the 9.2.27 Pseudomonas Exotoxin A (PE) immunotoxin (IT) efficiently kills melanoma cells through inhibition of protein synthesis followed by some morphologic and biochemical features of apoptosis, a different cell killing mechanism than the one caused by Dacarbazine (DTIC), a chemotherapeutic drug used to treat malignant melanoma. To examine whether induced DTIC resistance also is a determining factor for the effectiveness of 9.2.27PE IT, we developed a DTIC resistant subline, FEMX-200DR, from the DTIC sensitive cell line FEMX. The cell variants were treated with 9.2.27PE, an IT binding to the high molecular weight-melanoma associated antigen (HMW-MAA) expressed on most malignant melanoma cells. The IT was equally effective in killing the FEMX-200DR and the FEMX cells, and the cell death was primarily caused by inhibition of protein synthesis. The DNA repair enzyme and apoptotic marker PARP, a substrate of caspase-3, was inactivated, although we observed only a minor activation of caspase-3 and caspase-8, intracellular proteases involved in apoptosis. In addition to being DTIC resistant, the FEMX-200DR cells were also more resistant to apoptosis than the parent cells as a 3 times higher concentration of the apoptotic inducer Staurosporine was needed to obtain IC50. Furthermore, in early passage malignant melanoma cell lines established from lymph node metastases, the 9.2.27PE caused a time-dependent and dose-dependent decrease in cell viability independent of their DTIC sensitivity. These findings show that the 9.2.27PE IT efficiently can cause cell death in malignant melanoma cells independent of their level of resistance to apoptosis and DTIC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445347     DOI: 10.1097/CJI.0b013e3181c54991

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  Immunotoxins: a promising treatment modality for metastatic melanoma?

Authors:  Karianne Risberg; Oystein Fodstad; Yvonne Andersson
Journal:  Ochsner J       Date:  2010

2.  Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Authors:  Hong Zhou; John W Marks; Walter N Hittelman; Hideo Yagita; Lawrence H Cheung; Michael G Rosenblum; Jeffrey A Winkles
Journal:  Mol Cancer Ther       Date:  2011-05-17       Impact factor: 6.261

3.  Combined pitavastatin and dacarbazine treatment activates apoptosis and autophagy resulting in synergistic cytotoxicity in melanoma cells.

Authors:  Abeer Al-Qatati; Saeb Aliwaini
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

4.  Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.

Authors:  Karianne Risberg; Øystein Fodstad; Yvonne Andersson
Journal:  PLoS One       Date:  2011-09-07       Impact factor: 3.240

5.  p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.

Authors:  Karine Flem-Karlsen; Christina Tekle; Tove Øyjord; Vivi A Flørenes; Gunhild M Mælandsmo; Øystein Fodstad; Caroline E Nunes-Xavier
Journal:  Sci Rep       Date:  2019-04-09       Impact factor: 4.379

6.  The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.

Authors:  Merete Thune Wiiger; Hemaseh Bideli; Oystein Fodstad; Kjersti Flatmark; Yvonne Andersson
Journal:  J Ovarian Res       Date:  2014-02-15       Impact factor: 4.234

7.  Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Authors:  Y Andersson; O Engebraaten; S Juell; S Aamdal; P Brunsvig; Ø Fodstad; S Dueland
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.